Archive for the ‘ophthalmic diagnostic agents’ Category

IC-Green

IC-GREEN

Sterile

Rx only

IC-GREEN Description

IC-GREEN™ is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. It is packaged with Aqueous Solvent consisting of Sterile Water for Injection used to dissolve the indocyanine green. IC-GREEN™ is to be administered intravenously.

Indocyanine green is a water soluble, tricarbocyanine dye with a peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e]indol-2-ylidene]-1,3,5- heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide, inner salt, sodium salt. IC-GREEN™ has a pH of approximately 6.5 when reconstituted. Each vial of IC-GREEN™ contains 25 mg of indocyanine green as a sterile lyophilized powder.

IC-GREEN – Clinical Pharmacology

Following intravenous injection, IC-GREEN™ is rapidly bound to plasma protein, of which albumin is the principle carrier (95%). IC-GREEN™ undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. IC-GREEN™ is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin. These characteristics make IC-GREEN™ a helpful index of hepatic function.

The plasma fractional disappearance rate at the recommended 0.5 mg/kg dose has been reported to be significantly greater in women than in men, although there was no significant difference in the calculated value for clearance.

Indications and Usage for IC-GREEN

For determining cardiac output, hepatic function and liver blood flow, and for ophthalmic angiography.

Contraindications

IC-GREEN™ contains sodium iodide and should be used with caution in patients who have a history of allergy to iodides.

Warnings

Anaphylactic deaths have been reported following IC-GREEN™ administration during cardiac catheterization.

Precautions

General

IC-GREEN™ Powder and Solution: IC-GREEN™ is unstable in aqueous solution and must be used within 6 hours. However, the dye is stable in plasma and whole blood so that samples obtained in discontinuous sampling techniques may be read hours later. Sterile techniques should be used in handling the dye solution as well as in the performance of the dilution curves.

IC-GREEN™ (indocyanine green for injection) powder may cling to the vial or lump together because it is freeze-dried in the vials.

Drug Interactions

Heparin preparations containing sodium bisulfite reduce the absorption peak of IC-GREEN™ in blood and, therefore, should not be used as an anticoagulant for the collection of samples for analysis.

Drug/ Laboratory Test Interactions

Radioactive iodine uptake studies should not be performed for at least a week following the use of IC-GREEN™.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No studies have been performed to evaluate the carcinogenicity, mutagenicity, or impairment of fertility.

Pregnancy

Pregnanacy Category C

Animal Reproduction studies have not been conducted with IC-GREEN™. It is also not known whether IC-GREEN™ can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. IC-GREEN™ should be given to a pregnant woman only if clearly indicated.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when IC-GREEN™ is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have been established.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Adverse Reactions

Anaphylactic or urticarial reactions have been reported in patients with or without history of allergy to iodides. If such reactions occur, treatment with the appropriate agents, e.g., epinephrine, antihistamines, and corticosteroids should be administered.

Overdosage

There are no data available describing the signs, symptoms, or laboratory findings accompanying overdosage. The LD

IC-GREEN Dosage and Administration

INDICATOR-DILUTION STUDIES

IC-GREEN™ permits recording of the indicator-dilution curves for both diagnostic and research purpose independently of fluctuations in oxygen saturation. In the performance of dye dilution curves, a known amount of dye is usually injected as a single bolus as rapidly as possible via a cardiac catheter into selected sites in the vascular system. A recording instrument (oximeter or densitometer) is attached to a needle or catheter for sampling of the dye-blood mixture from a systemic arterial sampling site.

Under sterile conditions, the IC-GREEN™ powder should be dissolved with the Aqueous Solvent provided for this product, and the solution used within 6 hours after it is prepared. If a precipitate is present, discard the solution. The amount of solvent to be used can be calculated from the dosage form which follows. It is recommended that the syringe used for injection of the dye be rinsed with this diluent. Isotonic saline should be used to flush the residual dye from the cardiac catheter into the circulation so as to avoid hemolysis. With the exception of the rinsing of the dye injection syringe, saline is used in all other parts of the catheterization procedure.

This matter of rinsing the dye syringe with distilled water may not be critical, since it is known that an amount of sodium chloride sufficient to make an isotonic solution may be added to dye that has first been dissolved in distilled water. This procedure has been used for constant-rate injection techniques without precipitation of the dye.

The usual doses of IC-GREEN™ which have been used for dilution curves are as follows:

Adults – 5.0 mg

These doses of the dye are usually injected in a mL volume. An average of five dilution curves are required in the performance of a diagnostic cardiac catheterization. The total dose of dye injected should be kept below 2 mg/kg.

To quantitate the dilution curves, standard dilutions of IC-GREEN™ in whole blood are made as follows. It is strongly recommended that the same dye that was used for the injections be used in the preparation of these standard dilutions. The most concentrated dye solution is made by accurately diluting 1 mL of the 5 mg/mL dye with 7 mL of distilled water. This concentration is then successively halved by diluting 4 mL of the previous concentration with 4 mL of distilled water. (If a 2.5 mg/mL concentration was used for the dilution curves, 1 mL of the 2.5 mg/mL dye is added to 3 mL of distilled water to make the most concentrated “standard” solution. This concentration is then successively halved by diluting 2 mL of the previous concentration with 2 mL of distilled water.) Then 0.2 mL portions (accurately measured from a calibrated syringe) of these dye solutions are added to 5 mL aliquots of the subject’s blood, giving final concentrations of the dye in blood beginning with 24.0 mg/liter, approximately (actual concentration depends on the exact volume of dye added). This concentration is, of course, successively halved in the succeeding aliquots of the subject’s blood. These aliquots of blood containing known amounts of dye, as well as a blank sample of which 0.2 mL of saline containing no dye has been added, are then passed through the detecting instrument and a calibration curve is constructed from the deflections recorded.

HEPATIC FUNCTION STUDIES

Due to its absorption spectrum, changing concentrations of IC-GREEN™ (indocyanine green for injection) in the blood can be monitored by ear densitometry or by obtaining blood specimens at timed intervals. The technique for both methods is as follows.

The patient should be studied in a fasting, basal state. The patient should be weighed and the dosage calculated on the basis of 0.5 mg/kg of body weight.

Under sterile conditions, the IC-GREEN™ powder should be dissolved with the Aqueous Solvent provided. Exactly 5 mL of aqueous solvent should be added to the 25 mg vial giving 5 mg of dye per mL of solution.

Inject the correct amount of dye into the lumen of an arm vein as rapidly as possible, without allowing the dye to escape outside the vein. (If the photometric method is used, prior to injecting IC-GREEN™, withdraw 6 mL of venous blood from the patient’s arm for serum blank and standard curve construction, and through the same needle, inject the correct amount of dye.)

Ear oximetry has also been used and makes it possible to monitor the appearance and disappearance of IC-GREEN™ without the necessity of withdrawal and spectrophotometric analysis of blood samples for calibration. An ear densitometer which has a compensatory photo-electric cell to correct for changes in blood volume and hematocrit, and a detection photocell which registers levels has been described. This device permits simultaneous measurement of cardiac output, blood volume and hepatic clearance of IC-GREEN™

Using the ear densitometer, a dosage of 0.5 mg/kg in normal subjects gives the following clearance pattern.

      

Photometric Method

A typical curve obtained by plotting dye concentration versus optical density is shown opposite. Percent retention can be read from this plot.

If more accurate results are desired, a curve using the patient’s blood and the vial of IC-GREEN™ being used in the determination can be constructed as follows:

A single 20-minute sample (withdrawn from a vein in the opposite arm to that injected) is allowed to clot, centrifuged and its optical density is determined at 805 nm using the patient’s normal serum as the blank. Dye concentration is read from the curve above. A single 20-minute sample of serum in healthy subjects should contain no more than 4% of the initial concentration of the dye. The use of percentage retention is less accurate than percentage disappearance rate, but provides reproducible results. Hemolysis does not interfere with a reading.

To calculate the percentage disappearance rate, obtain samples at 5, 10, 15 and 20 minutes after injecting the dye. Prepare the sample as in the previous section and measure the optical densities at 805 nm, using the patient’s normal serum as the blank. The IC-GREEN™ concentration in each timed specimen can be determined by using the concentration curve illustrated. Plot values on semilogarithmic paper.

Specimens containing IC-GREEN™ should be read at the same temperature since its optical density is influenced by temperature variations.

Normal Values

Percentage disappearance rate in healthy subjects is 18-24% per minute. Normal biological half-time is 2.5 – 3.0 minutes.

OPHTHALMIC ANGIOGRAPHY STUDIES

The excitation and emission spectra (Figure 1) and the absorption spectra (Figure 2) of IC-GREEN™ make it useful in ophthalmic angiography. The peak absorption and emission of IC-GREEN™ lie in a region (800-850 nm) where transmission of energy by the pigment epithelium is more efficient than in the region of visible light energy. IC-GREEN™ also has the property of being nearly 98% bound to blood protein, and therefore, excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature. It is, therefore, useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera.

Dosages up to 40 mg IC-GREEN™ dye in 2 mL of aqueous solvent have been found to give optimal angiograms, depending on the imaging equipment and technique used. The antecubital vein injected IC-GREEN™ dye bolus should immediately be followed by a 5 mL bolus of normal saline.

Clinically, angiograms of uniformly good quality can be assured only after taking care to optimize the contributions of all possible factors such as, patient cooperation and dye injection. The foregoing injection regimen is designed to provide delivery of a spatially limited dye bolus of optimal concentration to the choroidal vasculature following intravenous injection.

How is IC-GREEN Supplied

IC-GREEN™ is supplied in a kit (NDC 17478-701-02) containing six 25 mg IC-GREEN™ vials and six 10 mL Aqueous Solvent ampules:

STORAGE

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].

Akorn inc.

Manufactured for: Akorn, Inc.,

IR00N

Rev. 06/07

More IC-GREEN resources

Fluoracaine

Fluoracaine Drops

Fluoracaine Drops are used for:

Aiding in certain eye procedures.

Fluoracaine Drops are a combination disclosing agent and local anesthetic. It makes damaged areas of the eye easier to detect. It also works on nerves in the eye to decrease pain.

Do NOT use Fluoracaine Drops if:

Contact your doctor or health care provider right away if any of these apply to you.

Before using Fluoracaine Drops:

Some medical conditions may interact with Fluoracaine Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

Some MEDICINES MAY INTERACT with Fluoracaine Drops. Because little, if any, of Fluoracaine Drops are absorbed into the blood, the risk of it interacting with another medicine is low.

Ask your health care provider if Fluoracaine Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Fluoracaine Drops:

Use Fluoracaine Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Fluoracaine Drops.

Important safety information:

Do not use more than the recommended dose or for longer than prescribed without checking with your doctor.

Possible side effects of Fluoracaine Drops:

All medicines may cause side effects, but many people have no, or minor, side effects.

Temporary burning, stinging, or redness of the eye.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); gray, ground glass-like appearance of the eye; mental or mood changes; pain, irritation, or persistent redness of the eye; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects at

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (

Store Fluoracaine Drops in the refrigerator, between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. Fluoracaine Drops may be stored at room temperature for up to 1 month. Store away from heat, moisture, and light. Keep Fluoracaine Drops out of the reach of children and away from pets.

General information:

This information is a summary only. It does not contain all information about Fluoracaine Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Flucaine

Flucaine Drops

Flucaine Drops are used for:

Aiding in certain eye procedures.

Flucaine Drops are a combination disclosing agent and local anesthetic. It makes damaged areas of the eye easier to detect. It also works on nerves in the eye to decrease pain.

Do NOT use Flucaine Drops if:

Contact your doctor or health care provider right away if any of these apply to you.

Before using Flucaine Drops:

Some medical conditions may interact with Flucaine Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

Some MEDICINES MAY INTERACT with Flucaine Drops. Because little, if any, of Flucaine Drops are absorbed into the blood, the risk of it interacting with another medicine is low.

Ask your health care provider if Flucaine Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Flucaine Drops:

Use Flucaine Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Flucaine Drops.

Important safety information:

Do not use more than the recommended dose or for longer than prescribed without checking with your doctor.

Possible side effects of Flucaine Drops:

All medicines may cause side effects, but many people have no, or minor, side effects.

Temporary burning, stinging, or redness of the eye.

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); gray, ground glass-like appearance of the eye; mental or mood changes; pain, irritation, or persistent redness of the eye; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects at

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (

Store Flucaine Drops in the refrigerator, between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. Flucaine Drops may be stored at room temperature for up to 1 month. Store away from heat, moisture, and light. Keep Flucaine Drops out of the reach of children and away from pets.

General information:

This information is a summary only. It does not contain all information about Flucaine Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

AK-Fluor

AK-FLUOR

1 INDICATIONS AND USAGE

AK-FLUOR

2 DOSAGE AND ADMINISTRATION

2.1 Dosing

Adult Dose

The recommended dosage of AK-FLUOR

Pediatric Dose

For children, the dose is 7.7 mg/kg (actual body weight) up to a maximum of 500 mg, via intravenous infusion calculated on the basis of 35 mg for each 10 lbs. (4.54 kg) of body weight.

2.2 Preparation for Administration

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not mix or dilute with other solutions or drugs.

2.3 Administration

Inject the dose (over 5-10 seconds is normally recommended) into the antecubital vein, after taking precautions to avoid extravasation. A syringe, filled with AK-FLUOR

Reduction in dose from 500 mg to 200 mg of AK-FLUOR

DOSAGE FORMS AND STRENGTHS

AK-FLUOR

AK-FLUOR

CONTRAINDICATIONS

4.1 Hypersensitivity

AK-FLUOR

WARNINGS AND PRECAUTIONS

5.1 Respiratory Reactions

Caution should be exercised in patients with a history of allergy or bronchial asthma. An emergency tray should always be available.

If a potential allergy is suspected, an intradermal skin test may be performed prior to intravenous administration, i.e., 0.05 mL injected intradermally to be evaluated 30 to 60 minutes following injection. Given the sensitivity and specificity of skin testing, a negative skin test is not proof that a patient is not allergic to fluorescein.

5.2 Severe local tissue damage

Extravasation during injection can result in severe local tissue damage due to high pH of fluorescein solution. The following complications resulting from extravasation of fluorescein have been noted to occur: Sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median nerve in the antecubital area. Complications resulting from extravasation can cause severe pain in the arm for up to several hours. When extravasation occurs, the injection should be discontinued and conservative measures to treat damaged tissue and to relieve pain should be implemented. [see

ADVERSE REACTIONS

6.1 Skin and urine discoloration

The most common reaction is discoloration of the skin and urine. Skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours.

6.2 Gastrointestinal Reaction

The next most common adverse reaction is nausea. Vomiting, and gastrointestinal distress have also occurred. A strong taste may develop after injection.

6.3 Hypersensitivity Reactions

Symptoms and signs of hypersensitivity have occurred. Generalized hives and itching, bronchospasm and anaphylaxis have been reported. [see

6.4 Cardiopulmonary Reactions

Syncope and hypotension may occur. Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely. [see

6.5 Neurologic Reactions

Headache may occur. Convulsions may rarely occur following injection.

6.6 Thrombophlebitis

Thrombophlebitis at the injection site has been reported. Extravasation of the solution at the injection site causes intense pain at the site and a dull aching pain in the injected arm. [see

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Adequate animal reproduction studies have not been conducted with fluorescein sodium. It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

Fluorescein sodium has been demonstrated to be excreted in human milk. Caution should be exercised when fluorescein sodium is administered to a nursing woman.

8.4 Pediatric Use

Pediatric patients have been included in clinical studies. No overall differences in safety or effectiveness have been observed between pediatric and adult patients.

8.5 Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

DESCRIPTION

AK-FLUOR

MW = 376.27

AK-FLUOR

Active: fluorescein sodium (equivalent to fluorescein 10 % w/v, 100 mg/mL)

Inactives: Sodium Hydroxide and/or Hydrochloric Acid may be used to adjust pH (8.3 to 9.8), and Water for Injection.

AK-FLUOR

Active: fluorescein sodium (equivalent to fluorescein 25% w/v, 250 mg/mL)

Inactives: Sodium Hydroxide and/or Hydrochloric Acid may be used to adjust pH (8.3 to 9.8), and Water for Injection.

CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent areas/structures.

12.3 Pharmacokinetics

Distribution.

Within 7 to 14 seconds after IV administration into the antecubital vein, fluorescein usually appears in the central retinal artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade 6 to 12 hours after dosing. Various estimates of volume of distribution indicate that fluorescein distributes into interstitial space (0.5 L/kg).

Metabolism.

Fluorescein is metabolized to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose.

Excretion.

Fluorescein and its metabolite are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

There have been no long-term studies done using fluorescein in animals to evaluate carcinogenic potential.

16 HOW SUPPLIED/STORAGE AND HANDLING

AK-FLUOR

(NDC 17478-253-10) 5 mL, single dose vials in a package of 12.

AK-FLUOR

(NDC 17478-250-20) 2 mL, single dose vials in a package of 12.

AK-FLUOR

17 PATIENT COUNSELING INFORMATION

After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see

Rx only

Manufactured by:

FL00N

More AK-FLUOR resources

Free T-Mobile phones on sale | Thanks to Best Savings Accounts, Conveyancing Fees and Used Cars